Friday, September 23, 2016

Celontin


Celontin is a brand name of methsuximide, approved by the FDA in the following formulation(s):


CELONTIN (methsuximide - capsule; oral)



  • Manufacturer: PARKE DAVIS

    Approved Prior to Jan 1, 1982

    Strength(s): 150MG, 300MG [RLD]

Has a generic version of Celontin been approved?


No. There is currently no therapeutically equivalent version of Celontin available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Celontin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Celontin.

See also...

  • Celontin Consumer Information (Wolters Kluwer)
  • Celontin Consumer Information (Cerner Multum)
  • Celontin Kapseals Advanced Consumer Information (Micromedex)
  • Methsuximide Consumer Information (Wolters Kluwer)
  • Methsuximide Consumer Information (Cerner Multum)
  • Methsuximide Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Ridaura


Ridaura is a brand name of auranofin, approved by the FDA in the following formulation(s):


RIDAURA (auranofin - capsule; oral)



  • Manufacturer: PROMETHEUS LABS

    Approval date: May 24, 1985

    Strength(s): 3MG [RLD]

Has a generic version of Ridaura been approved?


No. There is currently no therapeutically equivalent version of Ridaura available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ridaura. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Ridaura.

See also...

  • Ridaura Consumer Information (Wolters Kluwer)
  • Ridaura Consumer Information (Cerner Multum)
  • Auranofin Consumer Information (Wolters Kluwer)
  • Auranofin Consumer Information (Cerner Multum)
Posted by at No comments:
Labels:

Sectral


Sectral is a brand name of acebutolol, approved by the FDA in the following formulation(s):


SECTRAL (acebutolol hydrochloride - capsule; oral)



  • Manufacturer: PROMIUS PHARMA

    Approval date: December 28, 1984

    Strength(s): EQ 200MG BASE [AB], EQ 400MG BASE [RLD][AB]

Has a generic version of Sectral been approved?


Yes. The following products are equivalent to Sectral:


acebutolol hydrochloride capsule; oral



  • Manufacturer: AMNEAL PHARM

    Approval date: December 30, 1999

    Strength(s): EQ 200MG BASE [AB], EQ 400MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: April 24, 1995

    Strength(s): EQ 200MG BASE [AB], EQ 400MG BASE [AB]


  • Manufacturer: WATSON LABS

    Approval date: October 18, 1995

    Strength(s): EQ 200MG BASE [AB], EQ 400MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sectral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Sectral.

See also...

  • Sectral Consumer Information (Wolters Kluwer)
  • Sectral Consumer Information (Cerner Multum)
  • Sectral Advanced Consumer Information (Micromedex)
  • Sectral AHFS DI Monographs (ASHP)
  • Acebutolol Consumer Information (Wolters Kluwer)
  • Acebutolol Consumer Information (Cerner Multum)
  • Acebutolol Advanced Consumer Information (Micromedex)
  • Acebutolol Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Revatio


Revatio is a brand name of sildenafil, approved by the FDA in the following formulation(s):


REVATIO (sildenafil citrate - solution; intravenous)



  • Manufacturer: PFIZER

    Approval date: November 18, 2009

    Strength(s): EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML) [RLD]

REVATIO (sildenafil citrate - tablet; oral)



  • Manufacturer: PFIZER

    Approval date: June 3, 2005

    Strength(s): EQ 20MG BASE [RLD]

Has a generic version of Revatio been approved?


No. There is currently no therapeutically equivalent version of Revatio available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Revatio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pyrazolopyrimidinone antianginal agents
    Patent 5,250,534
    Issued: October 5, 1993
    Inventor(s): Bell; Andrew S. & Brown; David & Terrett; Nicholas K.
    Assignee(s): Pfizer Inc.
    Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 - C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
    Patent expiration dates:

    • March 27, 2012
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • September 27, 2012
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 7, 2012 - TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING

    • November 7, 2012 - PEDIATRIC EXCLUSIVITY

    • November 20, 2012 - NEW DOSAGE FORM

    • May 20, 2013 - PEDIATRIC EXCLUSIVITY

See also...

  • Revatio Consumer Information (Drugs.com)
  • Revatio Consumer Information (Wolters Kluwer)
  • Revatio Injection Consumer Information (Wolters Kluwer)
  • Revatio Consumer Information (Cerner Multum)
  • Revatio Advanced Consumer Information (Micromedex)
  • Revatio Intravenous Advanced Consumer Information (Micromedex)
  • Sildenafil Consumer Information (Wolters Kluwer)
  • Sildenafil Injection Consumer Information (Wolters Kluwer)
  • Sildenafil Consumer Information (Cerner Multum)
  • Sildenafil Advanced Consumer Information (Micromedex)
  • Sildenafil Intravenous Advanced Consumer Information (Micromedex)
  • Sildenafil Citrate AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Sensipar


Sensipar is a brand name of cinacalcet, approved by the FDA in the following formulation(s):


SENSIPAR (cinacalcet hydrochloride - tablet; oral)



  • Manufacturer: AMGEN

    Approval date: March 8, 2004

    Strength(s): EQ 30MG BASE, EQ 60MG BASE, EQ 90MG BASE [RLD]

Has a generic version of Sensipar been approved?


No. There is currently no therapeutically equivalent version of Sensipar available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sensipar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Calcium receptor-active molecules
    Patent 6,011,068
    Issued: January 4, 2000
    Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
    Assignee(s): NPS Pharmaceuticals, Inc.
    The Brigham and Women's Hospital
    The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
    Patent expiration dates:

    • March 8, 2018
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Calcium receptor-active molecules
    Patent 6,031,003
    Issued: February 29, 2000
    Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
    Assignee(s): NPS Pharmaceuticals, Inc.
    The Brigham and Women's Hospital
    The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
    Patent expiration dates:

    • December 14, 2016
      ✓ 
      Patent use: METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL


    • December 14, 2016




  • Calcium receptor-active compounds
    Patent 6,211,244
    Issued: April 3, 2001
    Inventor(s): Van Wagenen; Bradford C. & Moe; Scott T. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
    Assignee(s): NPS Pharmaceuticals, Inc.
    The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca.sup.2+ on a calcium receptor.
    Patent expiration dates:

    • October 23, 2015
      ✓ 
      Patent use: METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Calcium receptor-active molecules
    Patent 6,313,146
    Issued: November 6, 2001
    Inventor(s): Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
    Assignee(s): NPS Pharmaceuticals, Inc.
    The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
    Patent expiration dates:

    • December 14, 2016
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Rapid dissolution formulation of a calcium receptor-active compound
    Patent 7,829,595
    Issued: November 9, 2010
    Inventor(s): Lawrence; Glen Gary & Alvarez; Francisco J. & Lin; Hung-Ren H. & Ju; Tzuchi R.
    Assignee(s): Amgen Inc.
    The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
    Patent expiration dates:

    • September 22, 2026
      ✓ 
      Patent use: METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 8, 2011 - ORPHAN DRUG EXCLUSIVITY

    • February 25, 2014 - TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY

    • February 25, 2014 - INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL

    • February 25, 2018 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Sensipar Consumer Information (Drugs.com)
  • Sensipar Consumer Information (Wolters Kluwer)
  • Sensipar Consumer Information (Cerner Multum)
  • Sensipar Advanced Consumer Information (Micromedex)
  • Sensipar AHFS DI Monographs (ASHP)
  • Cinacalcet Consumer Information (Wolters Kluwer)
  • Cinacalcet Consumer Information (Cerner Multum)
  • Cinacalcet Advanced Consumer Information (Micromedex)
  • Cinacalcet AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Thursday, September 22, 2016

Sensorcaine


Sensorcaine is a brand name of bupivacaine, approved by the FDA in the following formulation(s):


SENSORCAINE (bupivacaine hydrochloride - injectable; injection)



  • Manufacturer: APP PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 0.25% [AP], 0.5% [AP], 0.75% [AP]

Has a generic version of Sensorcaine been approved?


Yes. The following products are equivalent to Sensorcaine:


bupivacaine hydrochloride injectable; injection



  • Manufacturer: HOSPIRA

    Approved Prior to Jan 1, 1982

    Strength(s): 0.25% [AP], 0.5% [AP], 0.75% [AP]


  • Manufacturer: HOSPIRA

    Approval date: February 17, 1986

    Strength(s): 0.5% [AP]


  • Manufacturer: HOSPIRA

    Approval date: February 17, 1987

    Strength(s): 0.25% [AP], 0.25% [AP]


  • Manufacturer: HOSPIRA

    Approval date: March 3, 1987

    Strength(s): 0.25% [AP], 0.5% [AP], 0.5% [AP], 0.75% [AP], 0.75% [AP]


  • Manufacturer: SAGENT STRIDES

    Approval date: October 18, 2011

    Strength(s): 0.25% [AP], 0.5% [AP]

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE (bupivacaine hydrochloride injectable; injection)



  • Manufacturer: INTL MEDICATED

    Approval date: January 9, 2002

    Strength(s): 0.25% [AP], 0.5% [AP], 0.75% [AP]


  • Manufacturer: SAGENT STRIDES

    Approval date: October 18, 2011

    Strength(s): 0.25% [AP], 0.5% [AP], 0.75% [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sensorcaine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Sensorcaine.

See also...

  • Sensorcaine Solution Consumer Information (Wolters Kluwer)
  • Sensorcaine Consumer Information (Cerner Multum)
  • Bupivacaine Solution Consumer Information (Wolters Kluwer)
  • Bupivacaine in Dextrose Solution Consumer Information (Wolters Kluwer)
  • Bupivacaine Consumer Information (Cerner Multum)
  • Bupivacaine Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Rimso-50


Rimso-50 is a brand name of dimethyl sulfoxide, approved by the FDA in the following formulation(s):


RIMSO-50 (dimethyl sulfoxide - solution; intravesical)



  • Manufacturer: BIONICHE PHARMA

    Approved Prior to Jan 1, 1982

    Strength(s): 50% [RLD][AT]

Has a generic version of Rimso-50 been approved?


No. There is currently no therapeutically equivalent version of Rimso-50 available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rimso-50. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Rimso-50.

See also...

  • Rimso-50 Consumer Information (Cerner Multum)
  • Rimso-50 Advanced Consumer Information (Micromedex)
  • Dimethyl Sulfoxide Consumer Information (Wolters Kluwer)
  • Dimethyl sulfoxide Consumer Information (Cerner Multum)
  • Dimethyl sulfoxide Intravesical Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)